Copanlisib Hydrochloride

Copanlisib hydrochloride is an antineoplastic agent.

Specific Drugs

It is essential that the manufacturer's labeling be consulted for more detailed information on interactions with this drug, including possible dosage adjustments. Interaction highlights:

• CYP3A Inducers: Avoid concomitant use with strong CYP3A inducers.1

• CYP3A Inhibitors: Reduce the copanlisib dose to 45 mg when concomitantly administered with strong CYP3A inhibitors.1

Advise the patient to read the FDA-approved patient labeling (Patient Information).1

• Infections: Advise patients that copanlisib hydrochloride can cause serious infections that may be fatal. Advise patients to immediately report symptoms of infection.1

• Hyperglycemia: Advise patients that an infusion-related increase in blood glucose may occur, and to notify their healthcare provider of any symptoms such as pronounced hunger, excessive thirst, headaches, or frequently urinating. Blood glucose levels should be well controlled prior to infusion.1

• Hypertension: Advise patients that an infusion-related increase in blood pressure may occur, and to notify their healthcare provider of any symptoms such as dizziness, passing out, headache, and/or a pounding heart. Blood pressure should be normal or well controlled prior to infusion.1

• Non-infectious pneumonitis: Advise patients of the possibility of pneumonitis, and to report any new or worsening respiratory symptoms including cough or difficulty breathing.1

• Neutropenia: Advise patients of the need for periodic monitoring of blood counts and to notify their healthcare provider immediately if they develop a fever or any signs of infection.1

• Severe cutaneous reactions: Advise patients that a severe cutaneous reaction may occur, and to notify their healthcare provider if they develop skin reactions (rash, redness, swelling, itching or peeling of the skin).1

• Pregnancy: Advise females of reproductive potential to use effective contraceptive methods and to avoid becoming pregnant during treatment with copanlisib hydrochloride and for at least one month after the last dose. Advise patients to notify their healthcare provider immediately in the event of a pregnancy or if pregnancy is suspected during copanlisib hydrochloride treatment. Advise males with female partners of reproductive potential to use effective contraception during treatment with copanlisib hydrochloride and for at least one month after the last dose.1

• Lactation: Advise women not to breastfeed during treatment with copanlisib hydrochloride and for at least 1 month after the last dose.1

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.